Recent searches

No recent searches

Search options

Only available when logged in.
mstdn.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A general-purpose Mastodon server with a 500 character limit. All languages are welcome.

Administered by:

Server stats:

12K
active users

mstdn.social: AboutStatusProfiles directoryPrivacy policyTerms of service

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.4.1

#psychedelicresearch

5 posts3 participants0 posts today
Psychedelic Institute

Psychedelic Cognitive Behavioral Therapy: On Ketamine, Context and Competencies in "Assisted-Psychotherapy”

There are many tools to help a psychotherapist help clients learn to speak the language of cognitive behavioral therapy, especially tools which may help facilitate therapeutic alliance, including, but not limited to telehealth. #ketamine #mentalhealth #psychedelics #telehealth #psychedelicresearch #cbt #ketaminetherapy #psychedelictherapy psychedelicmentalhealth.net/ps

Psychedelic Institute of Mental Health & Family Therapy · Psychedelic Cognitive Behavioral Therapy: On Ketamine, Context and Competencies in "Assisted-Psychotherapy”There are many tools to help a psychotherapist help clients learn to speak the language of cognitive behavioral therapy, especially tools which may help facilitate therapeutic alliance, including, but not limited to telehealth.
Psychedelic Institute

psychedelicmentalhealth.net/ke Ketamine as an Adjunct Therapy for Refractory Cancer Pain: A Case Report (Emshoff, et al, 2025) While traditionally recognized for its anesthetic and dissociative effects, low-dose, subanesthetic ketamine can be useful in palliative care to manage severe, intractable pain. #ketamine #ketaminetherapy #cancer #painmanagement #palliativecare #psychedelicresearch #psychedelic #psychedelics #cancerpain

Psychedelic Institute of Mental Health & Family Therapy · Spotlight: Ketamine as an Adjunct Therapy for Refractory Cancer Pain: A Case Report (Emshoff, et al, 2025)"While traditionally recognized for its anesthetic and dissociative effects, low-dose, subanesthetic ketamine can be useful in palliative care to manage severe, intractable pain."
Psychedelic Institute

psychedelicmentalhealth.net/sp Spotlight: Early Response to Ketamine for Suicidal Crisis Reduces Suicidal Events at 3 Months (Pastre, et al, 2025) This is the first study demonstrating that early SI response to IV ketamine is associated with a reduced risk of suicidal events at 3 months. These findings support ketamine's unique antisuicidal properties beyond its antidepressant effects, highlighting its potential role in suicide prevention. #ketamine #suicide #mentalhealth #psychedelicresearch

Psychedelic Institute

Ketamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks (Gibuła-Tarłowska, et al, 2025) Ketamina: de un anestésico a un medicamento psiquiátrico: mecanismos de acción, aplicaciones clínicas y riesgos potenciales pubmed.ncbi.nlm.nih.gov/406493 #ketamine #ketamina #psychedelics #psicodelicos #psychedelicresearch #terapiaconketamina #ketaminetherapy #ketamineassistedpsychotherapy #saludmental #mentalhealth

PubMedKetamine-From an Anesthetic to a Psychiatric Drug: Mechanisms of Action, Clinical Applications and Potential Risks - PubMedKetamine, originally developed as an anesthetic, is gaining increasing attention due to its multifaceted pharmacological properties. In addition to its use in anesthesia, ketamine exerts potent analgesic effects via N-methyl-D-aspartate (NMDA) receptor antagonism, modulating pain perception and redu …
Psychedelic Institute

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach (Jylkkä, et al, 2025) La meditación y los psicodélicos facilitan tipos similares de ideas místicas, psicológicas y filosóficas-existenciales predictivas del bienestar sciencedirect.com/science/arti #psychedelics #ketamine #meditation #ketamina #psicodelicos #medicinapsicodelica #psychedelicresearch

*
Instituto Psicodélico

Mirá #uruguay este capítulo en el que participé sobre cómo la ketamina puede utilizarse en cuidados paliativos como una medicina psicodélica profundamente transformadora. — Psicodélicos en Cuidados Paliativos Psychedelics in Palliative Care: Ketamine Marcia Glass, ED. 2025, Oxford University Press academic.oup.com/book/60443/ch #psicodelicos #terapiaconketamina #ketamina #cuidadospaliativos #medicinapsicodelica #uruguay #psychedelicresearch #psychedelics #ketamine #psychedelic #palliativecare

Psychedelic Institute

nature.com/articles/s41386-025 Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression (Falchi-Carvalho, et al, 2025) #psychedelics #dmt #psychedelic #psychedelicresearch

NatureRapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression - NeuropsychopharmacologyDepression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current treatments, such as oral antidepressants, often take around 3 weeks to become effective, with no immediate anti-suicidal benefits. The field urgently needs innovative therapies that provide rapid relief. Psychedelics like psilocybin and ayahuasca have shown promising antidepressant effects; however, their long duration (several hours) makes them costly and impractical for public health systems. N,N-Dimethyltryptamine (DMT), an endogenous psychedelic also found in ayahuasca, offers a viable alternative with a short duration of action (10–20 min) and non-invasive inhalation administration. Unlike ayahuasca, which contains monoamine oxidase inhibitors, vaporized DMT acts quickly and poses fewer pharmacological interaction risks. This open-label trial evaluated inhaled DMT for TRD for the first time, within the framework of interventional psychiatry. Fourteen patients (Nfemale = 6) participated in a fixed-order, dose-escalation study (15 mg and 60 mg). The treatment was safe, well-tolerated, and produced manageable psychedelic effects with no serious adverse events. A subpopulation using antidepressants showed similar safety outcomes. Results showed rapid and sustained antidepressant effects, with an average reduction of 21.14 points on the Montgomery-Asberg Depression Rating Scale by day 7 (p < 0.001). The response rate was 85.71%, and the remission rate was 57.14% 7 days post-administration, lasting up to 3 months. Suicidal ideation significantly decreased, with no severe ideation the day after dosing. Vaporized DMT offers a non-invasive, time-efficient, and cost-effective alternative to other psychedelics and traditional antidepressants, supporting its role in interventional psychiatry and public health. Clinicaltrials.gov NCT06094907.
*
Nick Walker

This coming Monday, May 19, the OPEN Foundation will be hosting me and my esteemed friend & colleague Dr. Alicia Danforth for a conversation about autism & psychedelics!

It's free, it's on Zoom, and everything else I know about it can be found here:
open-foundation.org/events/onl

OPEN FoundationAutism and Psychedelics: A Conversation with Alicia Danforth and Nick Walker - OPEN FoundationPsychedelic-assisted therapy holds unique potential for supporting autistic and neurodivergent individuals—but also presents distinct challenges. Join Dr. Alicia Danforth and Dr. Nick Walker for an open conversation on neurodiversity, autism, and the importance of designing inclusive, empowering treatment protocols. Moderated by Daan Keiman, psychedelic chaplain and educational lead at the OPEN Foundation.
#autistic#autisticwellbeing#autisticvoices
TrendingLive feeds
About